+161.4%
RSP vs MRNA
+915.3%
-753.9%
-39.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -3.4% | +3.6% | +0.3% |
| 7D | +2.4% | -12.1% | +14.5% | +2.8% |
| 30D | +4.3% | -1.3% | +5.6% | +4.2% |
| 3M | -0.3% | +250.9% | -251.3% | -7.0% |
| 6M | +9.8% | +343.0% | -333.2% | +0.9% |
| YTD | +16.8% | +657.4% | -640.6% | +3.9% |
| 1Y | +19.5% | +794.9% | -775.4% | +5.2% |
| 3Y | +65.1% | +218.1% | -153.0% | +50.0% |
| 5Y | +48.7% | -3.4% | +52.1% | +38.5% |
| All | +161.4% | +915.3% | -753.9% | +130.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling